Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Prescribing Hope: The Placebo Effect Endures

Philip Seo, MD, MHS  |  Issue: June 2018  |  June 21, 2018

The placebo effect is, however, more than just mind over matter. Functional magnetic resonance imaging demonstrates that placebos reduce activity in the dorsal anterior cingulate cortex, the thalamus and the mid and anterior insula, regions of the brain that are activated by painful stimuli. The placebo effect is likely mediated by multiple neurotransmitters, including endogenous opioids, and the effect can be partially reversed by naloxone.11

Placebos & Modern Medicine

I can’t think of a single person who has explicitly prescribed a sugar pill. That is not to say, however, that the placebo has disappeared from the practice of modern medicine. In 2008, a survey was conducted of 600 internists and 600 rheumatologists regarding their attitudes toward prescribing placebo therapies. Although actual sugar pills were rarely used, more than half of the respondents admitted to having suggested vitamins, over-the-counter analgesics or other medications they did not believe would directly affect the underlying pathophysiology of the patient’s diagnosis. In the majority of cases, these medications were not explicitly described as a placebo; they were described instead as “a medicine not typically used for this condition, but one that might benefit you.”12

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In their discussion, the authors of this study note, “The desire to promote positive therapeutic expectations among patients is prevalent among the surveyed physicians. … Physicians might have multiple, possibly conflicting, beliefs and motivations for recommending active placebo treatments. They might believe that a given benign and safe treatment … might have some finite chance of a beneficial pharmacological effect, despite remaining unproved for the symptom or condition at hand; or, at the very least, such treatments might promote positive expectations in patients or to help the patient to feel like they are being taken care of. This perceived need to administer something in the absence of other proved effective treatments for chronic symptomatic conditions … might motivate physicians to prescribe placebo treatments.”

In other words, we are prescribing hope. A folk saying (misattributed variously to William Osler, Edward Trudeau and Hippocrates) says the role of the physician is “to cure sometimes, to relieve often, to comfort always.”13 In that spirit, I rarely try to dissuade my patients from taking glucosamine, coenzyme Q-10, ginseng, black seed oil or the host of compounds they ask me about in clinic. Over the years, I have learned it’s difficult to predict what a patient might find a comfort. As long as the cost is modest and the risk is low, I think many of these interventions are worth trying, at least for a limited time, even if I think it might just be a placebo.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:patient communicationpatient managementplacebo

Related Articles

    How to Discuss Anti-Inflammatory Diets & Supplements with Your Patients

    June 9, 2023

    My patients ask me almost daily what kind of diet they should be on, or if there are certain supplements they should try. And a growing amount of evidence shows lifestyle and dietary factors may contribute to disease risk and outcomes in rheumatic disease. Thus, rheumatologists and rheumatology professionals are being called upon by patients…

    Is Acupuncture for Pain a Placebo Treatment?

    November 1, 2010

    An examination of the evidence

    The End of the Beginning: COVID-19 Vaccines & Other Conundrums

    December 9, 2020

    “It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEAfter some fits and starts, I finally struck…

    Space & Other Races

    October 19, 2020

    On April 5, 1950, a small group of scientists met in Silver Spring, Md., to talk about geophysics. I know this is not the most riveting way to start, but if you stick with me, I promise the story will get much more interesting. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEThis group of scientists met to discuss…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences